The rumor mill has started to turn again about the possibility of Novartis AG shedding some eye disease assets but reports of the death of ophthalmology research at the Swiss major would appear to be greatly exaggerated.
Novartis has reportedly hired an advisor to gauge interest in some of the drugs in its ophthalmology portfolio, according to Bloomberg. One of the assets listed as being potentially up for grabs is Xiidra (lifitegrast), its dry eye drug which was bought for $3.4bn upfront from Takeda Pharmaceutical Co. Ltd. four years ago but is still struggling to make an impact commercially
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
